Video
Neurotech platform delivers biological agent over extended period to slow progression of retinal-based diseases
Author(s):
Rich Small, CEO of Neurotech, provides updates on the company’s pipeline that is the culmination of nearly 2 decades of research.
Rich Small, CEO of Neurotech, provides updates on the company’s pipeline that is the culmination of nearly 2 decades of research with Sheryl Stevenson, Ophthalmology Times®’ Group Editorial Director, during the New Horizons Forum at the 2022 Glaucoma 360 meeting
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Related Videos
Related Content
